GlassScriptPhysician profile
Scott M Greaves
NPI 1750377974
$3,990.65
in general payments reported to CMS, 2019-2025
30 companies · $576 in 2025
The $576 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2020: $411 · 2021: $546 · 2022: $486 · 2023: $653 · 2024: $773 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,000 · Education: $1.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,999.70 |
| Education | $1.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $944.61 | 2019-2025 | |
| Glaxosmithkline, LLC. | $779.13 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $310.47 | 2019-2024 | |
| Lilly USA, LLC | $253.36 | 2019-2024 | Mounjaro |
| Novo Nordisk INC | $250.08 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $195.76 | 2019-2025 | Jardiance |
| Amgen INC. | $169.16 | 2019-2024 | Repatha, Otezla, Evenity |
| Merck Sharp & Dohme LLC | $131.84 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Janssen Pharmaceuticals, INC | $128.80 | 2019-2022 | |
| Biotronik Nro, INC. | $90.52 | 2025 | Prospera |
| Astrazeneca Pharmaceuticals LP | $74.33 | 2019-2024 | Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $66.32 | 2023-2024 | Trintellix |
| Amarin Pharma, INC. | $63.44 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $61.30 | 2021 | |
| Verity Pharmaceuticals INC. | $58.47 | 2025 | Tlando |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $55.43 | 2024-2025 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $49.88 | 2019-2020 | |
| Allergan, INC. | $40.05 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.54 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $29.23 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.71 | 2022 | |
| Antares Pharma, INC. | $27.32 | 2024 | Xyosted |
| Bausch Health US, LLC | $24.96 | 2023 | Aplenzin, Wellbutrin |
| Scilex Pharmaceuticals INC. | $21.95 | 2024 | |
| Eisai INC. | $21.38 | 2021 | |
| Exact Sciences Corporation | $19.36 | 2023 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $17.86 | 2025 | Rexulti |
| Acella Pharmaceuticals, LLC | $17.32 | 2024 | NP Thyroid 60 |
| Sanofi-Aventis U.S. LLC | $14.19 | 2022 | |
| Edwards Lifesciences Corporation | $11.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Greaves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.